Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats
- PMID: 17688
- DOI: 10.1111/j.2042-7158.1977.tb11309.x
Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats
Abstract
The elimination, distribution and anticoagulant activity of S(-)-, R(+)-, and R,S(+/-)- phenoprocoumon were determined in male Wistar-Lewis rats after intravenous injection of a single dose of 0.6 mg kg-1. From the plasma concentrations which elicited the same anticoagulant effect, S(-)-phenprocoumon was 4 to 5 times more potent than R(+)-phenprocouman. The potency of the racemate was between those of the enantiomers. The mean biologic half-life of the S(-)-enantiomer was shorter (12-5 h) than that of R(+)-phenprocoumon (17-8 h). No differences were observed in the apparent volume of distribution. However, the mean liver:plasma concentration ratio was higher for the S(-)-(6-9) than for the R(+)-enantiomer (5-2). At a total concentration of 16-8 microgram ml-1 the percentage of unbound drug in rat serum was significantly higher for the S(-)- (1-13%) than that for the R(+)-enantiomer (0.76%). Values obtained for the racemate were always between those of the enantiomers. It is concluded that stereoselective differences in the distribution between plasma and liver, and consequently in the rate of elimination are most likely due to stereoselective differences in serum protein binding. The greater anticoagulant potency of the S(-)- over the R(+)-enantiomer, cannot be explained primarily by the observed pharmacokinetic differences.
Similar articles
-
Effect of induction and inhibition of drug metabolism on pharmacokinetics and anticoagulant activity of the enantiomers of phenprocoumon in rats.Pharmacology. 1980;21(5):313-22. doi: 10.1159/000137446. Pharmacology. 1980. PMID: 7433511
-
Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats.J Pharmacokinet Biopharm. 1979 Dec;7(6):643-63. doi: 10.1007/BF01061212. J Pharmacokinet Biopharm. 1979. PMID: 529027
-
The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies.Clin Pharmacol Ther. 1976 Sep;20(3):342-9. doi: 10.1002/cpt1976203342. Clin Pharmacol Ther. 1976. PMID: 954354
-
The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.Clin Pharmacol Ther. 1987 Sep;42(3):312-9. doi: 10.1038/clpt.1987.154. Clin Pharmacol Ther. 1987. PMID: 3621786
-
Phenprocoumon.2024 Dec 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Dec 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000588 Free Books & Documents. Review.
Cited by
-
Species-dependent stereospecific serum protein binding of the oral anticoagulant drug phenprocoumon.Experientia. 1978 Oct 15;34(10):1323-5. doi: 10.1007/BF01981447. Experientia. 1978. PMID: 104885
-
Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity.Br J Pharmacol. 1988 Nov;95(3):675-82. doi: 10.1111/j.1476-5381.1988.tb11692.x. Br J Pharmacol. 1988. PMID: 3207986 Free PMC article.
-
Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.Eur J Clin Pharmacol. 2015 Dec;71(12):1461-5. doi: 10.1007/s00228-015-1912-1. Epub 2015 Sep 24. Eur J Clin Pharmacol. 2015. PMID: 26400679
-
Effect of serum protein binding on pharmacokinetics and anticoagulant activity of phenprocoumon in rats.J Pharmacokinet Biopharm. 1980 Apr;8(2):177-91. doi: 10.1007/BF01065192. J Pharmacokinet Biopharm. 1980. PMID: 7431221 No abstract available.
-
New oral anticoagulants: comparative pharmacology with vitamin K antagonists.Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. Clin Pharmacokinet. 2013. PMID: 23292752 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources